Although still in early development, HER3-DXd represents a biomarker-selected ADC strategy with potential relevance to recurrent/metastatic cervical cancer, especially in tumors exhibiting HER3 overexpression or PI3K pathway activation. This evidence concerns the gene PIK3CA and cervical carcinoma.